Minor Transplacental Passage of Fondaparinux in Vivo
- 29 April 2004
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 350 (18), 1914-1915
- https://doi.org/10.1056/nejm200404293501825
Abstract
Low-molecular-weight heparin remains the anticoagulant of choice for pregnant women with previous thromboembolic events. Fondaparinux (Arixtra, Sanofi-Synthelabo) is a chemically synthesized derivative of the natural pentasaccharide sequence that mediates the interaction of heparin with antithrombin.1 It has been recommended for prophylaxis against thromboembolism after hip or knee surgery.2,3Keywords
This publication has 5 references indexed in Scilit:
- Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux)Thrombosis Research, 2003
- Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitroThrombosis and Haemostasis, 2002
- The Pharmacokinetics of Fondaparinux Sodium in Healthy VolunteersClinical Pharmacokinetics, 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryThe New England Journal of Medicine, 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryThe New England Journal of Medicine, 2001